Glasdegib

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameGlasdegib
Drug Alias Name格拉德吉GlasdegibumGlasdegib maleate格拉地吉Daurismo +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseasePrimary Myelofibrosis +[10] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/11/21
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncH Lee Moffitt Cancer Center & Research InstitutePfizer Europe Ma Eeig
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterUniversity Of Colorado DenverHui Zhi Pharmaceutical (Dalian) Co Ltd
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursGraft vs Host DiseasePrimary Myelofibrosis +[7] 

Other Information

ATC CodeL01XJ03
Related LinksWikipediaDrugBankKEGG